Charles River Laboratories Intl. Inc (NYSE:CRL) Shares Purchased by Riverhead Capital Management LLC

Riverhead Capital Management LLC boosted its position in Charles River Laboratories Intl. Inc (NYSE:CRL) by 36.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,616 shares of the medical research company’s stock after buying an additional 1,492 shares during the period. Riverhead Capital Management LLC’s holdings in Charles River Laboratories Intl. were worth $797,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in shares of Charles River Laboratories Intl. by 1.3% in the 1st quarter. BlackRock Inc. now owns 4,587,801 shares of the medical research company’s stock valued at $666,379,000 after acquiring an additional 57,789 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Charles River Laboratories Intl. by 18.0% in the 1st quarter. AQR Capital Management LLC now owns 2,082,761 shares of the medical research company’s stock valued at $301,042,000 after purchasing an additional 317,001 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Charles River Laboratories Intl. by 49.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock valued at $138,804,000 after purchasing an additional 323,625 shares during the period. TimesSquare Capital Management LLC boosted its holdings in Charles River Laboratories Intl. by 5.1% during the second quarter. TimesSquare Capital Management LLC now owns 907,850 shares of the medical research company’s stock worth $128,824,000 after buying an additional 44,275 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in Charles River Laboratories Intl. by 6.8% during the second quarter. Fisher Asset Management LLC now owns 471,341 shares of the medical research company’s stock worth $66,883,000 after buying an additional 29,980 shares in the last quarter. Hedge funds and other institutional investors own 94.40% of the company’s stock.

Shares of CRL stock traded up $1.36 on Wednesday, reaching $131.04. 6,946 shares of the company were exchanged, compared to its average volume of 233,653. The company has a market cap of $6.35 billion, a price-to-earnings ratio of 21.81, a P/E/G ratio of 1.66 and a beta of 1.09. The business has a 50-day moving average price of $132.09 and a 200 day moving average price of $136.35. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59. Charles River Laboratories Intl. Inc has a 1 year low of $103.00 and a 1 year high of $149.07.



Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.55 by $0.08. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The firm had revenue of $657.60 million for the quarter, compared to analyst estimates of $662.61 million. During the same period last year, the company posted $1.62 EPS. Charles River Laboratories Intl.’s quarterly revenue was up 12.4% compared to the same quarter last year. As a group, equities analysts anticipate that Charles River Laboratories Intl. Inc will post 6.52 earnings per share for the current year.

In other news, insider David Ross Smith sold 1,249 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $130.36, for a total value of $162,819.64. Following the transaction, the insider now owns 19,327 shares in the company, valued at $2,519,467.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.80% of the stock is owned by corporate insiders.

A number of research analysts have weighed in on the stock. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Leerink Swann started coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They set an “outperform” rating on the stock. Svb Leerink began coverage on Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating and a $155.00 price target for the company. Finally, Zacks Investment Research cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $147.62.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: What are the advantages of the Stochastic Momentum Index?

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.